Lead mobilization during pregnancy
R. A. Russell,I. Odder,G. Thompson,E. Robertson,S. Fitzgerald
DOI: https://doi.org/10.5694/j.1326-5377.1986.tb113643.x
1986-01-01
Abstract:number of prescriptions that had been filled, the incidence rate per 1000 varied from 1.7 for one prescription to 10.4 for five or more prescriptions a statistically significant dose-response relationship. Therefore, this study demonstrates a biological gradient; as Sheffield and Batagol point out, no other data on Debendox in humans has shown this sort of trend. Controlling for the mother's age and the calendar time of the birth did not materially affect these conclusions. Embedded within this cohort study was a case-control study, consisting of 25 cases of pyloric stenosis each matched to four control subjects by the case mother's age, race, the season and year of birth, and the sex of the infant. This nested case-control study permitted a more detailed examination of other variables, including birth weight, length of gestation, birth order, timing of exposure and the use of other drugs. None of these variables had an important effect, with the exception of the timing of exposure; there appeared to be a peak in the odds ratios between the eighth and tenth weeks of pregnancy. Aselton et aI.'s results are consistent with those of Eskenazi and Bracken, who found an odds ratio of 4.3 for pyloric stenosis (950/0 confidence interval, 1.8-10.8).3 However, their results differ from those of Mitchell et aI., whose case-control study found no association between pyloric stenosis and maternal exposure to Bendectin (odds ratio = 1.0); 95% confidence interval, 0.7-1.4).' Various explanations for these differences have been suggested by Aselton et aI. Their paper concludes that their study provides some evidence to support a connection between the continuous use of Bendectin during pregnancy and pyloric stenosis, but that a causal interpretation for this connection is not yet warranted.' Ian Gordon, MSc Research Fellow Department of Community Medicine The University of Melbourne 159 Barry Street, Carlton, VIC 3053 I. Sheffield LJ, Batagol R. The creation of therapeutic orphans or, what have we learnt from the Debendox fiasco? Med J A ust 1985; 143: 143-147. 2. Aselton P, lick H, Chentow Sl, et al, Pyloric stenosis and maternal Bendectin exposure. Am J Epidemiol 1984; 120: 251-256. 3. Eskenazi B, Bracken MB. Bendectin (Debendox) as a risk factor for pyloric stenosis. Am J Obstet Gynecol 1982; 144: 919-924. 4. Mitchell A, Schwing! P; Rosenberg L, et al, Pyloric stenosis in relation to Bendectin use in pregnancy. Am J Epidemiol1983; 118: 433.